extra-US

R&D

Clinical trial expansion comes with complexity and increased risk, as each country has distinct regulatory requirements and contractual expectations.

News

AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.